473 results about "Regimen" patented technology

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

The present invention relates to methods for treating or reducing the severity of thyroid eye disease. In particular, the present invention provides methods for treating or reducing the severity of thyroid eye disease in patients in need thereof comprising administering an IGF-1R antagonist antibody according to specific dosage regimens. Pharmaceutical compositions comprising the IGF-1R antagonist antibody for use in the methods are also described.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention discloses an excrement character recognition and drug delivery closed-loop control method and system, and the system comprises an excrement collection and preprocessing module which is used for carrying out the automatic collection, preliminary physical and chemical character detection and sample preprocessing of the excrement of a patient; the multi-modal data analysis module is used for carrying out deep fusion analysis on the original multi-modal data output by the excrement collection and preprocessing module and carrying out diarrhea type diagnosis and severity evaluation; the drug delivery closed-loop control module is used for accurately and dynamically infusing drugs according to the diagnosis result of the multi-modal data analysis module; and the man-machine interaction and early warning module is used for monitoring and intervening the state of the system by medical staff and receiving important alarms. According to the invention, objective and continuous evaluation of excrement properties is realized, the drug dosage and scheme can be dynamically adjusted according to the properties, and the accuracy, individualization level and safety of diarrhea treatment of critical patients are significantly improved.

A diabetes management system adapted to determine adherence for a subject in treatment according to a basal insulin regimen, the system being adapted to receive regimen data. BG data and insulin injection data. If one or more insulin injections have not been received in accordance with the prescribed regimen and thus are missing, the system is adapted to calculate for each missing injection an expected dose response BG value. By comparing received BG data, corresponding to the missing insulin injections, it can be determined for a given confidence interval whether or not the subject has been in adherence with the basal insulin regimen.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The present invention provides specific dosage regimens for the treatment of generalized pustular psoriasis (GPP) with anti-interleukin-36R antibodies (anti-IL36R antibodies) which dosage regimens surprisingly provide for the rapid and sustained remission of pathological symptoms of GPP including e.g., flares caused by GPP.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.

The present disclosure features methods, e.g., dosing regimens, of treating cancer with SMARCA4 / SMARCA2 ATPase inhibitors.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention provides a traditional Chinese medicine for treating protrusion of lumbar intervertebral disc, and relates to the technical field of traditional Chinese medicines. Aiming at the core pathogenesis of qi stagnation and blood stasis, deficiency of liver and kidney and cold-dampness arthralgia of the lumbar intervertebral disc protrusion, a synergistic compatibility concept of promoting blood circulation to remove blood stasis, tonifying liver and kidney, dispelling cold-dampness and activating meridians to stop pain is adopted. The traditional Chinese medicine is prepared from 12 traditional Chinese medicines such as ligusticum wallichii, safflower, eucommia ulmoides and radix achyranthis bidentatae through an optimized process of crushing, extracting, concentrating and forming, and the dosage form comprises tablets, capsules or oral liquid. The core innovation lies in accurate matching of the formula, multi-target synergistic effect is achieved, and the problems that traditional Chinese medicine is slow in curative effect and poor in pertinence are solved. Clinical verifications show that the traditional Chinese medicine can relieve lumbar pain within 7 days and improve symptoms such as numbness of lower limbs and limited movement within 1-2 treatment courses, has the total effective rate of greater than or equal to 92%, is safe, has no obvious toxic or side effect, is suitable for patients with different types of lumbar disc herniation, and is convenient to take and high in cost performance.

The application belongs to the field of medicine, and particularly relates to application of a Danzhu Fuguan formula in preparation of a drug for treating idiopathic membranous nephropathy (IMN). The Danzhu Fuguan formula comprises the following raw materials in parts by weight: 25-35 parts of Danshen, 10-15 parts of Baizhu, 25-35 parts of Huangqi, 10-20 parts of Jinyinhua, 10-20 parts of Hujiang, 10-20 parts of Yujin, 10-15 parts of Fuling, 25-35 parts of Yiyiren and 10-15 parts of Qianghuo. Research shows that the Danzhu Fuguan formula can effectively reduce the 24-hour urine protein level of IMN patients, and the 24-hour urine protein level shows a significant downward trend with the extension of the treatment course; according to the IMN clinical efficacy standard, the total remission rate of patients receiving the Danzhu Fuguan formula treatment for 3 months is 37%, the total remission rate of patients receiving the treatment for 6 months is 50%, and the total remission rate of patients receiving the treatment for 12 months reaches 72%, and the remission rate increases significantly with the extension of the treatment course.

The invention discloses a method and a system for predicting preeclampsia risk of a pregnant woman based on computer implementation. The method integrates the concentration level of vitamin D (especially 25-hydroxyvitamin D) in serum of pregnant women, angiogenesis biomarkers (such as sFlt-1 / PlGF ratio), conventional clinical indexes (such as mean arterial pressure and body mass index) and personal medical history data. A machine learning algorithm (such as a random forest or a gradient lifting model) is adopted to carry out weighted analysis on the multi-dimensional data, and a dynamic and high-precision prediction model is constructed. The system comprises a data acquisition module, an intelligent prediction module and a clinical decision support module, and can provide real-time risk assessment and personalized intervention suggestions (such as a vitamin D supplement scheme) for medical staff, so that early warning and effective management of preeclampsia are realized, and the risk of pregnancy outcome caused by maternal and infant poor pregnancy is reduced.

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

A method of treating a tumor in a subject, the method comprises applying a tumor treating field to the tumor at a frequency between approximately 50 kHz and approximately 1,000 kHz; and delivering personalized ultra-fractionated adaptive radiotherapy (PULSAR) regimen.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

This invention provides the medical use of tyrosol in the preparation of formulations that reduce the toxicity of penicillin-thiazolic acid (PTA). It discloses a novel medical use of tyrosol in preparing formulations that reduce PTA toxicity. By using tyrosol to prevent and treat the residual toxicity of PTA, unnecessary antibiotic replacement regimens can be avoided, significantly reducing the economic burden. A method for preventing and treating PTA residual toxicity is provided, which can significantly reduce the toxicity of PTA and has good preventive and therapeutic effects. The prevention and treatment of PTA residual toxicity has significant socio-economic implications for controlling the hygiene and quality of animal-derived foods, protecting consumer health, and ensuring industrial production.

A method of determining a therapeutic regimen in a patient with cancer comprising determining in a sample from the patient the tumor mutation burden (TMB) and loss of heterozygosity (LOH), wherein high TMB in combination with no LOH is indicative of a positive outcome when treated with a checkpoint inhibitor and high TMB with LOH is indicative of a poor outcome, is provided herein.

The present disclosure addresses the problem of providing a dosage regimen for an orally administered pharmaceutical composition that is for treating and / or preventing autosomal dominant polycystic kidney disease and that contains, as an active ingredient, tamibarotene. The present disclosure provides a pharmaceutical composition that is for treating or preventing autosomal dominant polycystic kidney disease, that contains tamibarotene, and that is to be orally administered to an autosomal dominant polycystic kidney disease patient in an amount of 1.4-5.5 mg / day, particularly about 4 mg / day, in terms of the tamibarotene.

A method for reducing adverse events associated with administering ecopipam, the method comprising dosing according to a specific weight range and an associated dose escalation regimen, and a further downward dosing regimen for discontinuation of ecopipam.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention relates to a medical treatment device (2000) comprising a compressed-air source (175), at least one substitution port (100) and a flushing port (101), each for establishing a fluidic connection between a fluid line (2002) of the treatment device (2000) and the exterior of the treatment device (2000). By specifically switching or activating the components already present in the medical treatment device (2000), such as the compressed-air source (175), valves (V22, V23, V24, V25, V26, V31, V32, V33, V42, V43) and / or pressure sources (131, 159, 169), i.e. pumps, it can advantageously be achieved that, at the end of the disinfection programme of the medical treatment device (2000) according to the invention, the flushing port (101) is emptied and the lines leading to the substitution port (100) are filled with liquid.